Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab maintenance therapy after concurrent chemoradiotherapy in unresectable stage III NSCLC
ChiCTR2100054107Phase 2Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Anhui Chest Hospital. Primary endpoint: 2-year survival rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100054107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054107.